Dificlir Gains European Approval

Astellas and partner Optimer Pharmaceuticals announced yesterday that regulators in Europe have given the green light to their antibiotic Dificlir. The European Commission has approved Dificlir (fidaxomicin) for the treatment of Clostridium Difficile infections (CDI) in adults, which can cause severe diarrhoea. The approval is based on two Phase III trials which compared Dificlir with

Continue Reading